ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
Launched by CHRISTOPHER TESHIMA · Sep 20, 2011
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
Summary of Research Proposal
Background:
Colon and rectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality in Canada. Colonoscopy is the preferred screening modality for CRC and has been shown to decrease the likelihood of developing CRC as well as CRC-related mortality, particularly through the detection and removal of potentially pre-cancerous polyps, with the aim of preventing colon cancer, and for the diagnosis of early stage CRC that is more likely to be treatable and result in long-term survival. However, recent evidence suggests that colonoscopy has not bee...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult patient 18 years or older.
- • 2. Able to read \& write English.
- • 3. Undergoing colonoscopy at University of Alberta Hospital for any indication.
- Exclusion Criteria:
- • 1. Colonoscopy performed without prior purgative bowel prep.
- • 2. Patient with active, ongoing lower GI bleeding.
- • 3. Colonoscopy performed to attempt colonic decompression in acute colonic pseudo-obstruction (Ogilvie's syndrome).
- • 4. Colonoscopy for which propofol sedation is required.
- • 5. Inpatient colonoscopy performed by a trainee under staff supervision.
- • 6. Patient with previous colonic surgery.
- • 7. Patient with pacemaker or implantable cardioverter-defibrillator (ICD).
About Christopher Teshima
Christopher Teshima is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the clinical research landscape, Teshima focuses on facilitating innovative studies that adhere to rigorous ethical standards and regulatory compliance. His leadership emphasizes collaboration with healthcare professionals and stakeholders to ensure the successful design, execution, and analysis of clinical trials across various therapeutic areas. By prioritizing patient safety and data integrity, Christopher Teshima strives to contribute to the development of effective therapeutic interventions and enhance the overall quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Christopher W Teshima, MD FRCPC
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials